| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. (NCT02610075) | AstraZeneca | 2015-12-01 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (NCT02433626) | Critical Outcome Technologies Inc. | 2015-12-01 |
| Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host (NCT02732860) | University Health Network, Toronto | 2015-12-01 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification (NCT03171506) | University of Alabama at Birmingham | 2015-11-09 |
| Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (NCT02558348) | Advenchen Laboratories, LLC | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) (NCT02537444) | Acerta Pharma BV | 2015-11-01 |
| Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer (NCT02562365) | Xiaohua Wu MD | 2015-11-01 |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients (NCT02470299) | New Mexico Cancer Research Alliance | 2015-10-29 |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer (NCT02440425) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-20 |
| Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer (NCT05300828) | Seoul National University Hospital | 2015-10-19 |
| Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer (NCT03656809) | NYU Langone Health | 2015-10-15 |
| Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility (NCT02133703) | Georgetown University | 2015-10-01 |
| Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer (NCT02560818) | Centre Francois Baclesse | 2015-10-01 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (NCT02432378) | Roswell Park Cancer Institute | 2015-09-04 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer (NCT02545010) | National University Hospital, Singapore | 2015-09-01 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (NCT02948075) | NewVac LLC | 2015-09-01 |
| Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. (NCT02560337) | Vejle Hospital | 2015-09-01 |
| A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services (NCT02517554) | Abramson Cancer Center at Penn Medicine | 2015-08-01 |
| Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (NCT02539719) | Stemcentrx | 2015-08-01 |
| A Mind-body Intervention to Improve Body and/or Self Image (NCT02531997) | University of Michigan | 2015-08-01 |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02470585) | AbbVie | 2015-07-14 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors (NCT02952183) | Seoul National University Hospital | 2015-07-01 |
| Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors (NCT02684318) | Poveda, Andrés, M.D. | 2015-07-01 |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer (NCT02483104) | AbbVie | 2015-07-01 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT02389985) | NewLink Genetics Corporation | 2015-07-01 |
| Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer (NCT02458001) | University College, London | 2015-07-01 |
| Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer (NCT02383251) | ARCAGY/ GINECO GROUP | 2015-06-15 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (NCT02476955) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2015-06-09 |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib (NCT02340611) | University Health Network, Toronto | 2015-06-01 |
| A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation (NCT02432690) | Sumitomo Pharma America, Inc. | 2015-06-01 |
| Platine, Avastin and OLAparib in 1st Line (NCT02477644) | Arcagy Research | 2015-05-06 |
| Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 (NCT02326064) | Centre Hospitalier Departemental Vendee | 2015-05-01 |
| WISER After Ovarian Cancer - Exercise Pilot Study (NCT02529150) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (NCT02418624) | The Netherlands Cancer Institute | 2015-05-01 |
| Pillars4Life Trial (NCT02465892) | Duke University | 2015-05-01 |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (NCT02421588) | PharmaMar | 2015-05-01 |
| A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours (NCT03427073) | Almac Discovery | 2015-04-27 |
| BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older (NCT02393898) | Hoffmann-La Roche | 2015-04-23 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (NCT02417753) | National Cancer Institute (NCI) | 2015-04-03 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors (NCT02429700) | Beihua Kong | 2015-04-01 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |
| Writing About Experiences With Ovarian Cancer (NCT02593422) | University of Maryland, College Park | 2015-04-01 |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (NCT02429687) | Beihua Kong | 2015-04-01 |
| Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE) (NCT02374827) | University of Alabama at Birmingham | 2015-04-01 |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (NCT02354586) | Tesaro, Inc. | 2015-03-23 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors (NCT02367352) | Millennium Pharmaceuticals, Inc. | 2015-03-19 |
| BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment (NCT02326844) | National Cancer Institute (NCI) | 2015-03-02 |
| Study of Predictive Factors of Chemoresistance in Ovarian Cancer (NCT02878122) | Rennes University Hospital | 2015-03-01 |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT02278783) | University of Utah | 2015-03-01 |
| Prevalence of BRCA in Patients With Ovarian Cancer (NCT02222883) | AGO Research GmbH | 2015-03-01 |
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer (NCT02399592) | Vejle Hospital | 2015-03-01 |
| Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (NCT02387125) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-02-28 |
| Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (NCT02354131) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2015-02-15 |
| Short-course HIPEC in Advanced Epithelial Ovarian Cancer (NCT02249013) | Professor Fernando Figueira Integral Medicine Institute | 2015-02-01 |
| A Trial of Vigil for Participants With Ovarian Cancer (NCT02346747) | Gradalis, Inc. | 2015-02-01 |
| Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy (NCT02372864) | University Medical Center Groningen | 2015-02-01 |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer (NCT02117817) | Rutgers, The State University of New Jersey | 2015-02-01 |
| Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) (NCT02346955) | Famewave Ltd. | 2015-02-01 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (NCT02203513) | National Cancer Institute (NCI) | 2015-01-20 |
| Circulating Tumor DNA Exposure in Peripheral Blood (NCT03517332) | Quantgene Inc. | 2015-01-01 |
| Cancer Prevention in Women With a BRCA Mutation (NCT02225015) | Women's College Hospital | 2015-01-01 |
| Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (NCT02321228) | University Medical Center Nijmegen | 2015-01-01 |
| The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer (NCT02856841) | Cairo University | 2015-01-01 |
| The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients (NCT03019315) | National Taiwan University Hospital | 2015-01-01 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (NCT02960594) | Inovio Pharmaceuticals | 2014-12-01 |
| Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer (NCT02317705) | On Target Laboratories, LLC | 2014-12-01 |
| Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (NCT02307500) | Istituto Clinico Humanitas | 2014-12-01 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (NCT02327078) | Incyte Corporation | 2014-11-26 |
| Yoga Practice for Breast or Ovarian Cancer Patients (NCT02305498) | Memorial Sloan Kettering Cancer Center | 2014-11-24 |
| Venous Thromboembolic Complications in Ovarian Cancer (NCT02480790) | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | 2014-11-01 |
| Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention (NCT02287519) | Dana-Farber Cancer Institute | 2014-11-01 |
| Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers (NCT02269293) | Memorial Sloan Kettering Cancer Center | 2014-10-13 |
| Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (NCT02262455) | Santa Maria Biotherapeutics | 2014-10-01 |
| Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) (NCT02312167) | Institut Mutualiste Montsouris | 2014-10-01 |
| DOD Long-Term Survivors of Ovarian Cancer (NCT02321735) | Massachusetts General Hospital | 2014-09-01 |
| Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer (NCT02237690) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2014-09-01 |
| PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (NCT02055690) | The Christie NHS Foundation Trust | 2014-09-01 |
| PTX-200 and Carboplatin in Ovarian Cancer (NCT01690468) | Prescient Therapeutics, Ltd. | 2014-09-01 |
| Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses (NCT02218502) | Maastricht University Medical Center | 2014-09-01 |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (NCT01610869) | University College, London | 2014-08-01 |
| Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients (NCT02785887) | Azienda USL 4 Prato | 2014-08-01 |
| Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies (NCT01880996) | Sheba Medical Center | 2014-08-01 |
| Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging (NCT02792959) | Institut Bergonié | 2014-08-01 |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT02118285) | Masonic Cancer Center, University of Minnesota | 2014-07-28 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) (NCT02163720) | ARCAGY/ GINECO GROUP | 2014-07-10 |
| Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. (NCT02221076) | Mauna Kea Technologies | 2014-07-01 |
| Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage (NCT03150121) | Sheba Medical Center | 2014-06-29 |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) (NCT02179515) | National Cancer Institute (NCI) | 2014-06-28 |
| Biomarkers for Gynecologic Cancer (NCT02178462) | Ajinomoto Co., Inc. | 2014-06-01 |
| Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (NCT02188550) | Sinai Hospital of Baltimore | 2014-06-01 |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma (NCT02083536) | University of Miami | 2014-05-01 |
| Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics (NCT02144311) | Memorial Sloan Kettering Cancer Center | 2014-05-01 |
| Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. (NCT02341118) | University Health Network, Toronto | 2014-05-01 |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02121990) | Memorial Sloan Kettering Cancer Center | 2014-04-21 |